MedChemComm p. 593 - 598 (2017)
Update date:2022-08-04
Topics:
Davis, Rachel E.
Zhang, Zheng
Blagg, Brian S. J.
Inhibition of the Hsp90 C-terminus is an attractive therapeutic paradigm for the treatment of cancer, however the developmental space of C-terminal inhibitors is limited. It was hypothesized that the combination of two previously identified scaffolds into a single structure could provide a platform for which to probe the three-dimensional space within the Hsp90 C-terminal binding pocket. The resulting chimeric compounds displayed anti-proliferative activity at low micromolar concentrations and manifested inhibitory activity in an Hsp90-dependent rematuration assay. Initial structure-activity relationships suggest that this new scaffold binds Hsp90 in a conformation different from that of the parent compounds, and consequently, provides a new opportunity to develop more efficacious inhibitors of the Hsp90 C-terminal binding pocket.
View MoreShandong Hongxiang Zinc Co., Ltd
Contact:086-0311-66187879
Address:DaWang developing zone
Hubei Lansun Biochemical Pharmaceutical Co., Ltd
Contact:714-6395977
Address:No. 81 Pengcheng Avenue, economic and technological development zone, Huangshi City, Hubei Province,China
shandong lukang animal & plant drug trading co.,ltd.
Contact:15853765968
Address:floor 9, lukang ,jingying building,#173,taibai building west road,jining city,shandong,china
Hubei Xiangxi Chemical Industry Co.,Ltd
Contact:+86-710-3454830
Address:No.7, Daqing East Road, Xiangfan City, Hubei Province, China
website:http://www.finerchem.com
Contact:+86-531-88989536
Address:New Material Industry Park, Jinan Ciyt, China
Doi:10.1021/ol006988j
(2001)Doi:10.1021/jo00969a006
(1972)Doi:10.1021/ol006751n
(2001)Doi:10.1039/b000568l
(2000)Doi:10.1021/acscatal.7b01543
(2017)Doi:10.1016/0045-6535(94)90282-8
(1994)